Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9672235rdf:typepubmed:Citationlld:pubmed
pubmed-article:9672235lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:9672235lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:9672235lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:9672235lifeskim:mentionsumls-concept:C1268930lld:lifeskim
pubmed-article:9672235lifeskim:mentionsumls-concept:C0537225lld:lifeskim
pubmed-article:9672235lifeskim:mentionsumls-concept:C0206415lld:lifeskim
pubmed-article:9672235pubmed:dateCreated1998-9-17lld:pubmed
pubmed-article:9672235pubmed:abstractTextThe ability to recognize HIV antigens is lost early in HIV-1 infection. Individuals with nonprogressive HIV disease have been observed to mount strong immune responses against the virus and have become a paradigm to emulate with immune-based therapies. Highly active antiviral drug therapy (HAART) has now become the standard of care for HIV-1-infected individuals. Because HIV-specific anergy occurs early in HIV infection, HAART initiated after primary infection may not reconstitute HIV-specific immune function. We have been investigating the effects of an immune-based therapy, called REMUNE, in HIV-1-seropositive individuals. REMUNE has been observed to stimulate HIV-1-specific immune function measured by delayed-type hypersensitivity, lymphocyte proliferation, Th1 cytokine, and beta-chemokine production. Multiple Phase II studies and a Phase III clinical end-point study are ongoing in thousands of seropositive individuals in order to test the clinical utility of REMUNE. The clinical testing of REMUNE and other promising immune-based therapies may provide additional treatment modalities useful in the chronic management of HIV-1.lld:pubmed
pubmed-article:9672235pubmed:languageenglld:pubmed
pubmed-article:9672235pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9672235pubmed:citationSubsetIMlld:pubmed
pubmed-article:9672235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9672235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9672235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9672235pubmed:statusMEDLINElld:pubmed
pubmed-article:9672235pubmed:monthJunlld:pubmed
pubmed-article:9672235pubmed:issn0889-2229lld:pubmed
pubmed-article:9672235pubmed:authorpubmed-author:CarloD JDJlld:pubmed
pubmed-article:9672235pubmed:authorpubmed-author:JensenF CFClld:pubmed
pubmed-article:9672235pubmed:authorpubmed-author:TheofanGGlld:pubmed
pubmed-article:9672235pubmed:authorpubmed-author:MossR BRBlld:pubmed
pubmed-article:9672235pubmed:authorpubmed-author:DaigleA EAElld:pubmed
pubmed-article:9672235pubmed:authorpubmed-author:RichieriS PSPlld:pubmed
pubmed-article:9672235pubmed:authorpubmed-author:SavaryJ RJRlld:pubmed
pubmed-article:9672235pubmed:authorpubmed-author:GiermakowskaW...lld:pubmed
pubmed-article:9672235pubmed:issnTypePrintlld:pubmed
pubmed-article:9672235pubmed:volume14 Suppl 2lld:pubmed
pubmed-article:9672235pubmed:ownerNLMlld:pubmed
pubmed-article:9672235pubmed:authorsCompleteYlld:pubmed
pubmed-article:9672235pubmed:paginationS167-75lld:pubmed
pubmed-article:9672235pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9672235pubmed:meshHeadingpubmed-meshheading:9672235-...lld:pubmed
pubmed-article:9672235pubmed:meshHeadingpubmed-meshheading:9672235-...lld:pubmed
pubmed-article:9672235pubmed:meshHeadingpubmed-meshheading:9672235-...lld:pubmed
pubmed-article:9672235pubmed:meshHeadingpubmed-meshheading:9672235-...lld:pubmed
pubmed-article:9672235pubmed:meshHeadingpubmed-meshheading:9672235-...lld:pubmed
pubmed-article:9672235pubmed:meshHeadingpubmed-meshheading:9672235-...lld:pubmed
pubmed-article:9672235pubmed:meshHeadingpubmed-meshheading:9672235-...lld:pubmed
pubmed-article:9672235pubmed:meshHeadingpubmed-meshheading:9672235-...lld:pubmed
pubmed-article:9672235pubmed:year1998lld:pubmed
pubmed-article:9672235pubmed:articleTitleA primer on HIV type 1-specific immune function and REMUNE.lld:pubmed
pubmed-article:9672235pubmed:affiliationThe Immune Response Corporation, Carlsbad, California 92008, USA.lld:pubmed
pubmed-article:9672235pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9672235pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9672235lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9672235lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9672235lld:pubmed